CD3-CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance

Blood

Volumn 89, Issue 8, 1997, Pages 2966-2974

  Drénou, Bernard ^a   Lamy, Thierry ^b   Amiot, Laurence ^b   Fardel, Olivier ^b   Caulet Maugendre, Sylvie ^b   Sasportes, Maryline ^b   Diebold, Jacques ^b   Le Prisé, Pierre Yves ^b   Fauchet, Renée ^b  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD2 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; GRANZYME B; PERFORIN; T LYMPHOCYTE RECEPTOR;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENOTYPE; HUMAN; IMMUNOCHEMISTRY; MALE; MULTIDRUG RESISTANCE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL;

EID: 1842407749     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.8.2966     Document Type: Article

References (49)

1. Lennert K, Feller AC: Histopathologie der Non-Hodgkin Lymphome. (Nach der aktualiesierten Kiel Klassification) Heidelberg, Germany, Springer-Verlag Berlin, 1990
2. Loughran TP: Clonal diseases of large granular lymphocytes. Blood 82:1, 1993
3. Griffin JD, Hercend T, Beveridge R, Sclossman SF: Characterization of an antigen expressed by human natural killer cells. J Immunol 130:2947, 1983
4. Sheridan W, Winton EF, Chan WC, Gordon DS, Vogler WR, Phillips C, Bongiovanni KF, Waldmann TA: Leukemia of non-T lineage natural killer cells. Blood 72:17001, 1988
5. Brody JP, Allen S, Schulman P, Chan WC, Friedman HD, Teichberg S, Koduru P, Cone RW, Loughran TP: Acute agranular CD4-positive natural killer cell leukemia. Comprehensive clinicopathologic studies including virologie and in vitro culture with inducing agents. Cancer 75:2474, 1995
6. - myeloid/natural killer cell acute leukemia: A previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3. Blood 84:244, 1994
7. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson P, Knowles DM, Mason D, Müller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361, 1994
8. Yamaguchi M, Ohno T, Oka K, Nishii K, Kawakami K, Miwa H, Kita K, Shirakawa S: Discordant reaction of Leu 4 and rabbit antihuman CD3 epsilon in sinonasal T-cell lymphoma. Int J Hematol 59:25, 1993
9. Fukuda J, Yoshihara T, Arai Y, Kaneko T, Zheng H, Mori S, Aoyama M, Masuda M, Motoji T, Oshimi K: Nasal NK-cell lymphoma. Rinsho Ketsueki 35:588, 1994
10. Kaneko T, Fukuda J, Yoshihara T, Zheng H, Mori S, Mizoguchi H, Oshimi K: Nasal natural killer (NK) cell lymphoma: Report of a case with activated NK cells containing Epstein-Barr virus and expressing CD21 antigen, and comparative studies of their phenotype and cytotoxicity with normal NK cells. Br J Hematol 91:355, 1995
11. Kanavaros P, Lescs MC, Brière J, Divine M, Galateau F, Joab I, Bosq J, Farcet JP, Reyes F, Gaulard P: Nasal T-cell lymphoma: A clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 81:2688, 1993
12. Suzumiya J, Takeshita M, Kimura N, Kikuchi M, Uchida T, Hisano S, Eura Y, Kozuru M, Nomura Y, Tomita K, Komiyama S, Okumura M: Expression of adult and fetal killer cell markers in sinonasal lymphomas. Blood 83:2255, 1994
13. Van Gorp J, Weiping L, Jacobse K, Yong-Huei L, Fen-Yuan L, De Weger RA, Li G: Epstein-Barr virus in nasal T-cell lymphomas (polymorphic reticulocytosis/midline malignant reticulocytosis) in western China. J Pathol 173:81, 1994
14. Jaffe ES, Chan JKC, Su IJ, Frizzera G, Mori S, Feller AC, Ho FCS: Report of the workshop on nasal and related extranodal angiocentric T/NK-cell lymphomas: Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 20:103, 1996
15. + "TCR silent peripheral T cell lymphomas" are natural killer cell lymphomas. Blood 87:1466, 1996
16. Imamura N, Kusunoki Y, Kajihara H, Okada K, Kuramoto A: Aggressive natural killer cell leukemia/lymphoma with N901-positive surface phenotype: Evidence for the existence of a third lineage in lymphoid cells. Acta Hematol 80:121, 1988
17. Imamura N, Kusunoki Y, Kawa-Ha K, Yumura K, Hatra J, Oda K, Abe K, Dohy H, Inada T, Kajihara H, Kuramoto A: Aggressive natural killer cell leukemia/lymphoma: Report of four cases and review of the literature. Br J Hematol 75:49, 1990
18. Wong KF, Chan JKC, Ng CS, Lee KC, Tsang WYW, Cheung MMC: CD56 (NKH1)-positive hematolymphoid malignancies: An aggressive neoplasm featuring frequent cutaneous/mucosal involvement, cytoplasmic azurophilic granules, and angiocentricity. Hum Pathol 23:798, 1992
19. Kern WF, Spier CM, Hanneman EH, Miller TP, Matzner M, Grogan TM: Neural cell adhesion molecule-positive peripheral T-cell lymphoma: A rare variant with a propensity for unusual sites of involvement. Blood 79:2432, 1992
20. Nakamura S, Suchi T, Koshikawa T, Tagagi N, Hayashi K, Koike K, Suzuki H, Ogura M, Kurita S, Oyama A, Ueda R, Takahashi T: Agressive rectal lymphoma of large granular lymphocytes with the histologic feature of an angiocentric growth pattern. Cancer 71:249, 1993
21. Adachi M, Maeda K, Takekawa M, Hinoda Y, Imai K, Sugiyama S, Yachi A: High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. Am J Hematol 47:278, 1994
22. Griffiths GM, Mueller C: Expression of perform and granzymes in vivo: Potential diagnosis markers for activated cytotoxic cells. Immunol Today 12:415, 1991
23. Oshimi K, Shinkai Y, Okumura K, Oshimi Y, Mizoguchi H: Perform gene expression in granular lymphocyte proliferative disorders. Blood 75:704, 1990
24. Nooter K, Sonneveld P: Clinical relevance of P-Glycoprotein expression in haematological malignancies. Leuk Res 18:233, 1994
25. Nare B, Prichard RK, Georges E: Characterization of Rhodamine 123 binding to P-glycoprotein in human multidrug-resistant cells. Mol Pharmacol 45:1145, 1994
26. Neyfackh AA: Use of fluorescent dyes as molecular probes for the study of multidrug resistance. Exp Cell Res 174:168, 1989
27. Coon JS, Wang Y, Bines SD, Markham PN, Chong ASF, Gebel HM: Multidrug resistance activity in human lymphocytes. Hum Immunol 32:134, 1991
28. Chaudary PM, Roninson IB: Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66:85, 1991
29. Lamy T, Grulois I, Drénou B, Fardel O, Le Prisé PY, Semana G, Genetet N, Fauchet R: High PgP activity measured by rhodamine 123 efflux assay in CD3, CD8, CD56 human lymphocytes and in CD3+, CD57+ large granular lymphocyte proliferative disorders (GLPD). Br J Hematol 87:112, 1994
30. Yamamoto T, Iwasaki T, Watanabe N, Oshimi K, Naito M, Tsuruo T, Kobayashi Y: Expression of multidrug resistance P-glycoprotein on peripheral blood mononuclear cells of patients with granular lymphocyte-proliferative disorders. Blood 81:1342, 1993
31. Wigzell H: Quantitative titrations of mouse H-2 antibodies using 51-Cr-labelled target cells. Transplantation 3:423, 1965
32. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning (ed 2). Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1989
33. Macintyre E, D'Auriol L, Amesland F, Loiseau P, Chen Z, Boumsell L, Galibert F, Sigaux F: Analysis of junctional diversity in the preferential V-J rearrangement for fresh T-acute lymphoblastic leukemia cells by in vitro gene amplification and direct sequencing. Blood 74:2053, 1989
34. Drénou B, Fardel O, Amiot L, Fauchet R: Detection of P-glycoprotein activity in normal and leukemic CD34 positive cells. Leuk Res 17:1031, 1993
35. Hamada H, Tsuruo T: Functional role for the 170-to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 83:7785, 1986
36. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Von Hoff DD, Roninson IB: Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87:7160, 1990
37. Lanier LL, Chang C, Spits H, Phillips JH: Expression of cytoplasmic CD3ε proteins in activated human adult NK cells and CD3γ, δ, ε complexes in fetal NK cells: Implications for the relationship of NK and T lymphocytes. J Immunol 149:1876, 1992
38. Lanier LL, Phillips JH: Inhibitory MHC class I receptors on NK cells. Immunol Today 17:86, 1996
39. Moretta A, Sivori S, Vitale M, Pende D, Morelli L, Augugliaro R, Bottino C, Moretta L: Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 182:875, 1995
40. Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P: The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med 181:1133, 1995
41. Moretta A, Vitale M, Sivori S, Bottino C, Morelli L, Augugliaro R, Barbaresi M, Pende D, Ciccone E, Lopez-Botet M, Moretta L: Human natural killer cell receptors for HLA class I molecules. Evidence that the Kp43 (CD94) molecule functions as receptor for HLA-B alleles. J Exp Med 180:545, 1994
42. Zambello R, Trentin L, Ciccone E, Bulian P, Agostini C, Moretta A, Moretta L, Semenzato G: Phenotypic diversity of natural killer (NK) populations in patients with NK-type lymphoproliferative disease of granular lymphocytes. Blood 81:2381, 1993
43. Yuen A, Sikic BI: Multidrug resistance in lymphomas. J Clin Oncol 12:2453, 1994
44. Ludesher C, Hilbe W, Eisterer W, Preuss E, Huber C, Gotwald M, Hofman J, Thaler J: Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay. J Natl Cancer Inst 85:1751, 1993
45. Grulois I, Fardel O, Drénou B, Lamy T, Le Prisé PY, Fauchet R: Multidrug activity in B cell chronic lymphocytic leukemia. Acta Haematol 94:78, 1995
46. Lamy T, Drénou B, Grulois I, Fardel O, Jacquelinet C, Goasguen J, Dauriac C, Amiot L, Bernard M, Fauchet R, Le Prisé PY: Multidrug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay. Leukemia 9:1549, 1995
47. Paietta E, Andersen J, Racevskis J, Ashigbi M, Cassileth P, Wiernik PH: Modulation of multidrug resistance in de nova acute myeloid leukemia: Variable efficacy of reverting agents in vitro. Blood Rev 9:47, 1995
48. - cases. Blood 86:2329, 1995
49. Chong ASF, Markham PN, Gebel HM, Bines S, Coon JS: Diverse multidrug-resistance modification agents inhibit cytolytic activity of natural killer cells. Cancer Immunol Immunother 36:133, 1993